Renal Anemia Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Jan 2024

Pages: 160

SKU: IRTNTR73276

Snapshot

Renal Anemia Therapeutics Market 2024-2028

The global renal anemia therapeutics market size is estimated to grow by USD 2.08 billion, at a CAGR of 7.59% between 2023 and 2028.

The frequency of new drug approvals by the US FDA in the global renal anemia therapeutics market has witnessed an upward swing in momentum in the past few years. For instance, in April 2021, the U.S. Food and Drug Administration approved Farxiga, a drug manufactured by AstraZeneca. This is effective against kidney dysfunction. Farxiga is an efficient drug to improve kidney outcomes and reduce the probability of cardiovascular death in patients with CKD. Similarly, in July 2021, the FDA approved Kerendia (finerenone), a tablet that can be used to reduce the risk of kidney dysfunction. Thus, such approvals will result in the launch of new drugs, which will drive market growth during the forecast period.

Technavio has segmented the market into Type, Distribution Channel, and Geography

The type segment includes IV and oral
The distribution channel segment includes hospital pharmacy, retail pharmacy, and online pharmacy
The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Renal Anemia Therapeutics Market During the Forecast Period?

To learn more about this report, Download Report Sample

Renal Anemia Therapeutics Market Segmentation by Type, Distribution Channel, and Geography Analysis

Type Analysis

IV

The market share growth by the IV segment will be significant during the forecast period. Medications administered through the IV route account for the leading segment in the global renal anemia therapeutics market due to increasing adoption and ease of absorption. Besides, ferric carboxymaltose Sucrose Dextran and others such as ferumoxytol and isomaltoside Ferric carboxymaltose is an iron complex that consists of a ferric hydroxide core that is stabilized by a carbohydrate shell. Sucrose is one of the oldest IV iron drugs.

Get a glance at the market contribution of various segments Download PDF Sample

The IV segment was valued at USD 2.46 billion in 2018. The first IV iron product in the market was high molecular weight iron dextran. However, the side effects of high molecular weight dextran products resulted in their removal from the market. Low molecular weight dextran products are the least expensive IV iron drugs that can be administered in a large single dose. The high demand for renal anemia therapeutics is being bolstered by the increasing frequency of product approvals in the IV iron drugs segment, which will result in the launch of several new drugs and drive the growth of the IV drugs segment in the global renal anemia therapeutics market during the forecast period.

Distribution Channel Analysis

Hospital pharmacy

Hospital pharmacies include pharmaceuticals that are purchased directly by hospitals from different pharmaceutical companies and used for the treatment of either outpatients or inpatients. The renal anemia drugs that are found in hospital pharmacies contain epoetin alfa, epoetin beta, and others. The primary aim of hospital pharmacies is to procure, store, and sell medications to patients in hospitals. Besides, the reach and influence of hospital pharmacies will continue to increase as they purchase or acquire controlling stakes in physician practices. Thus, such factors will drive market segment growth during the forecast period.

Retail pharmacy

Retail pharmacists sell medicine and medical-related products for renal anemia therapeutics to the general public and medical practitioners. Retail pharmacies are independent pharmacies or chain pharmacies. Retail pharmacies maintain records of dispensed medications and patient information. This documentation is essential for record-keeping, patient history, and potential future interactions. In addition to that, retail pharmacies are often located in easily accessible locations, including urban and suburban areas. Thus, such factors will contribute to the growth of retail pharmacies, which will strengthen market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America dominates the renal anemia therapeutics market in the region due to the increasing healthcare expenditure in countries such as the US and Canada. In addition, factors such as significant investment in the treatment of CKD and associated ailments such as renal anemia and the presence of several key market players make the US a significant contributor to the revenue of the renal anemia therapeutics market in the Americas.

Furthermore, revved approvals for certain formulations will boost the market. This is because these designations will provide fast approvals for the pipeline products and market exclusivities for the already approved drugs. This will encourage more vendors to conduct R&D activities and enter the market. In April 2021, The US FDA granted approved Farxiga oral tablets to reduce the risk of CKD. Additionally, The Patients' Access to Treatments Act, passed in March 2015, enables individuals to obtain proper treatments and limits healthcare costs. The law restricts cost-sharing requirements for medications and makes required medicines available for more individuals by reducing out-of-pocket expenses. Hence, such factors are expected to drive market growth in this region during the forecast period.

Buy Full Report Now

Key Renal Anemia Therapeutics Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Akebia Therapeutics Inc.: The company offers renal anemia therapeutics namely Vadadustat.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Renal Anemia Therapeutics Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth and forecasting. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.

Key Renal Anemia Therapeutics Market Drivers

The growing geriatric population is the key factor driving market growth. The prevalence of chronic diseases like CKD, is high among the aging population. There is a direct relationship between aging and susceptibility to infections, as it deteriorates the immune system. Apart from the impaired functioning of the immune system, the reduced functioning of organs also increases the chances of acquiring diseases such as CKD.

Moreover, the rise in the aging population led to an increase in expenditure on healthcare, disease diagnosis, and treatment. In addition, the elderly population requires renal anemia therapeutics regularly due to their low immunity and metabolism. Therefore, the increasing aging population will increase the adoption of renal anemia therapeutics, which will subsequently augment the growth of the market during the forecast period.

Significant Renal Anemia Therapeutics Market Trends

The growing adoption of biosimilars is the primary trend shaping market growth. A biosimilar, a therapeutic agent emulating a reference biologic, aligns with prevailing market trends and analysis. These biological medications undergo stringent regulatory processes, ensuring conformity to safety, efficacy, and quality standards akin to their reference counterparts. Biosimilar medications have the advantage of perhaps being less expensive than reference medication, which increases patient access and reduces costs in already tight healthcare budgets.

Additionally, in comparison to biologics, biosimilars are relatively more economical and provide similar efficacy and safety as the reference products. Market players like Pfizer offer biosimilar erythropoiesis-stimulating agents. Retacrit (Pfizer) acts as a biosimilar to Epogen/Procrit for the treatment of anemia associated with conditions such as CKD. Thus, the widespread availability and adoption of biosimilars will increase the sales of renal anemia therapeutics and will drive market growth during the forecast period.

Major Renal Anemia Therapeutics Market Challenges

Side effects of oral administration of renal anemia drugs is a challenge that affects market growth. The limitations associated with conventional oral therapies to treat anemia will reduce the demand for oral iron drugs. Oral therapies were considered the gold standard for the treatment of iron deficiency. Nevertheless, treating patients with oral iron drugs can be difficult due to poor gastrointestinal (GI) tolerance or absorption. Oral iron drugs need to be administered in multiple daily doses and have been associated with several side effects associated with GI tolerance.

Moreover, the absorption of oral iron drugs is limited by the decreased GI absorption caused by inflammation due to CKD. Inflammation increases the production of hepcidin - a protein produced in the liver - that controls iron homeostasis. The protein restricts the absorption of iron from the intestine and limits the release of iron from macrophages and hepatocytes. Therefore, side effects of oral administration of renal anemia drugs may impede market growth during the forecast period.

Buy Now Full Report

Key Renal Anemia Therapeutics Market Customer Landscape

The market analysis and report includes the adoption lifecycle of the market forecast, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market research and growth strategies.

Global Renal Anemia Therapeutics Market Customer Landscape

Segment Overview

The renal anemia therapeutics market report forecasts market growth analysis by revenue at global, regional & country levels and provides an analysis of the latest market growth and trends from 2018 to 2028.

Type Outlook
- IV
- Oral

Distribution Channel Outlook
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy

Region Outlook
- North America
  - The U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- Rest of World (ROW)
  - Argentina
  - Australia
  - Brazil

Renal Anemia Therapeutics Market Scope
Report Coverage	Details
Page number	160
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 7.59%
Market Growth 2024-2028	USD 2.08 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	6.97
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 35%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Akebia Therapeutics Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Covis Pharma GmbH, CSL Ltd., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., GlaxoSmithKline Plc, Japan Tobacco Inc., JCR Pharmaceticals Co. Ltd., Kirin Holdings Co. Ltd., Mitsubishi Chemical Group Corp., Pfizer Inc., Pharmacosmos AS, Sun Pharmaceutical Industries Ltd., Travere Therapeutics Inc., and Astellas Pharma Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Renal Anemia Therapeutics Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the renal anemia therapeutics market between 2024 and 2028
Precise estimation of the renal anemia therapeutics market size and its contribution to the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies' position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of renal anemia therapeutics market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global renal anemia therapeutics market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global renal anemia therapeutics market 2018 - 2022 ($ billion)

4.2 Type Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Type Segment 2018 - 2022 ($ billion)

4.3 Distribution Channel Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ billion)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

6.1 Market segments
- Exhibit 30: Chart on Type - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Type - Market share 2023-2028 (%)

6.2 Comparison by Type
- Exhibit 32: Chart on Comparison by Type
- Exhibit 33: Data Table on Comparison by Type

6.3 IV - Market size and forecast 2023-2028
- Exhibit 34: Chart on IV - Market size and forecast 2023-2028 ($ billion)
- Exhibit 35: Data Table on IV - Market size and forecast 2023-2028 ($ billion)
- Exhibit 36: Chart on IV - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on IV - Year-over-year growth 2023-2028 (%)

6.4 Oral - Market size and forecast 2023-2028
- Exhibit 38: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
- Exhibit 39: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
- Exhibit 40: Chart on Oral - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Oral - Year-over-year growth 2023-2028 (%)

6.5 Market opportunity by Type
- Exhibit 42: Market opportunity by Type ($ billion)
- Exhibit 43: Data Table on Market opportunity by Type ($ billion)

7 Market Segmentation by Distribution Channel

7.1 Market segments
- Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
- Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)

7.2 Comparison by Distribution Channel
- Exhibit 46: Chart on Comparison by Distribution Channel
- Exhibit 47: Data Table on Comparison by Distribution Channel

7.3 Hospital pharmacy - Market size and forecast 2023-2028
- Exhibit 48: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 49: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 50: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
- Exhibit 51: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)

7.4 Retail pharmacy - Market size and forecast 2023-2028
- Exhibit 52: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 53: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 54: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)

7.5 Online pharmacy - Market size and forecast 2023-2028
- Exhibit 56: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 57: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 58: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)

7.6 Market opportunity by Distribution Channel
- Exhibit 60: Market opportunity by Distribution Channel ($ billion)
- Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 China - Market size and forecast 2023-2028
- Exhibit 87: Chart on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 88: Data Table on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 89: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on China - Year-over-year growth 2023-2028 (%)

9.9 Germany - Market size and forecast 2023-2028
- Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.10 UK - Market size and forecast 2023-2028
- Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.11 Canada - Market size and forecast 2023-2028
- Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
- Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
- Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ billion)
- Exhibit 104: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption

11.4 Industry risks
- Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 109: Vendors covered

12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification

12.3 Akebia Therapeutics Inc.
- Exhibit 111: Akebia Therapeutics Inc. - Overview
- Exhibit 112: Akebia Therapeutics Inc. - Product / Service
- Exhibit 113: Akebia Therapeutics Inc. - Key offerings

12.4 Amgen Inc.
- Exhibit 114: Amgen Inc. - Overview
- Exhibit 115: Amgen Inc. - Product / Service
- Exhibit 116: Amgen Inc. - Key offerings

12.5 AstraZeneca Plc
- Exhibit 117: AstraZeneca Plc - Overview
- Exhibit 118: AstraZeneca Plc - Product / Service
- Exhibit 119: AstraZeneca Plc - Key news
- Exhibit 120: AstraZeneca Plc - Key offerings

12.6 Bayer AG
- Exhibit 121: Bayer AG - Overview
- Exhibit 122: Bayer AG - Business segments
- Exhibit 123: Bayer AG - Key news
- Exhibit 124: Bayer AG - Key offerings
- Exhibit 125: Bayer AG - Segment focus

12.7 Covis Pharma GmbH
- Exhibit 126: Covis Pharma GmbH - Overview
- Exhibit 127: Covis Pharma GmbH - Product / Service
- Exhibit 128: Covis Pharma GmbH - Key offerings

12.8 Daiichi Sankyo Co. Ltd.
- Exhibit 129: Daiichi Sankyo Co. Ltd. - Overview
- Exhibit 130: Daiichi Sankyo Co. Ltd. - Product / Service
- Exhibit 131: Daiichi Sankyo Co. Ltd. - Key news
- Exhibit 132: Daiichi Sankyo Co. Ltd. - Key offerings

12.9 Dr Reddys Laboratories Ltd.
- Exhibit 133: Dr Reddys Laboratories Ltd. - Overview
- Exhibit 134: Dr Reddys Laboratories Ltd. - Business segments
- Exhibit 135: Dr Reddys Laboratories Ltd. - Key offerings
- Exhibit 136: Dr Reddys Laboratories Ltd. - Segment focus

12.10 F. Hoffmann La Roche Ltd.
- Exhibit 137: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 138: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 139: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 140: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 141: F. Hoffmann La Roche Ltd. - Segment focus

12.11 GlaxoSmithKline Plc
- Exhibit 142: GlaxoSmithKline Plc - Overview
- Exhibit 143: GlaxoSmithKline Plc - Business segments
- Exhibit 144: GlaxoSmithKline Plc - Key news
- Exhibit 145: GlaxoSmithKline Plc - Key offerings
- Exhibit 146: GlaxoSmithKline Plc - Segment focus

12.12 Japan Tobacco Inc.
- Exhibit 147: Japan Tobacco Inc. - Overview
- Exhibit 148: Japan Tobacco Inc. - Business segments
- Exhibit 149: Japan Tobacco Inc. - Key news
- Exhibit 150: Japan Tobacco Inc. - Key offerings
- Exhibit 151: Japan Tobacco Inc. - Segment focus

12.13 JCR Pharmaceticals Co. Ltd.
- Exhibit 152: JCR Pharmaceticals Co. Ltd. - Overview
- Exhibit 153: JCR Pharmaceticals Co. Ltd. - Product / Service
- Exhibit 154: JCR Pharmaceticals Co. Ltd. - Key offerings

12.14 Kirin Holdings Co. Ltd.
- Exhibit 155: Kirin Holdings Co. Ltd. - Overview
- Exhibit 156: Kirin Holdings Co. Ltd. - Business segments
- Exhibit 157: Kirin Holdings Co. Ltd. - Key offerings
- Exhibit 158: Kirin Holdings Co. Ltd. - Segment focus

12.15 Mitsubishi Chemical Group Corp.
- Exhibit 159: Mitsubishi Chemical Group Corp. - Overview
- Exhibit 160: Mitsubishi Chemical Group Corp. - Business segments
- Exhibit 161: Mitsubishi Chemical Group Corp. - Key offerings
- Exhibit 162: Mitsubishi Chemical Group Corp. - Segment focus

12.16 Pfizer Inc.
- Exhibit 163: Pfizer Inc. - Overview
- Exhibit 164: Pfizer Inc. - Product / Service
- Exhibit 165: Pfizer Inc. - Key news
- Exhibit 166: Pfizer Inc. - Key offerings

12.17 Sun Pharmaceutical Industries Ltd.
- Exhibit 167: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 168: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 169: Sun Pharmaceutical Industries Ltd. - Key offerings

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 170: Inclusions checklist
- Exhibit 171: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 172: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 173: Research methodology
- Exhibit 174: Validation techniques employed for market sizing
- Exhibit 175: Information sources

13.5 List of abbreviations
- Exhibit 176: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

renal anemia therapeutics market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis